Levetiracetam Mechanisms of Action: From Molecules to Systems
Open accessThe DOI matches its Crossref record; 302 of the 303 references it cites were found in a registry or an index.
Abstract
Epilepsy is a chronic disease that affects millions of people worldwide. Antiepileptic drugs (AEDs) are used to control seizures. Even though parts of their mechanisms of action are known, there are still components that need to be studied. Therefore, the search for novel drugs, new molecular targets, and a better understanding of the mechanisms of action of existing drugs is still crucial. Levetiracetam (LEV) is an AED that has been shown to be effective in seizure control and is well-tolerable, with a novel mechanism of action through an interaction with the synaptic vesicle protein 2A (SV2A). Moreover, LEV has other molecular targets that involve calcium homeostasis, the GABAergic system, and AMPA receptors among others, that might be integrated into a single mechanism of action that could explain the antiepileptogenic, anti-inflammatory, neuroprotective, and antioxidant properties of LEV. This puts it as a possible multitarget drug with clinical applications other than for epilepsy. According to the above, the objective of this work was to carry out a comprehensive and integrative review of LEV in relation to its clinical uses, structural properties, therapeutical targets, and different molecular, genetic, and systemic action mechanisms in order to consider LEV as a candidate for drug repurposing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Across models of stress, epilepsy, and neurodegeneration, modulation of SV2A preserves synaptic structure and maintains transmission after plasticity induction [173,175,199].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Functionally, SV2A modulation limits the slide from induced plasticity to maladaptive remodeling and relapse-like behavior [175,199,205].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“After ketamine or other plasticity-promoting interventions, preserving vesicle cycling and maintaining a competent readily releasable pool appear crucial for sustaining gains; animal studies link antidepressant durability to synaptic integrity supported by SV2A pathways and complementary signaling through ERK and calcium channels [199,201,205].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Levetiracetam restores vesicle fusion fidelity, rescues basal transmission, and normalizes synaptic protein composition, effects that depend on direct SV2A engagement and extend to hippocampal volume and plasticity recovery [173,175,199].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [199]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In stress-sensitized and developmental perturbation paradigms, levetiracetam reverses anxiety-like, cognitive, and social deficits while rebalancing hippocampal and mesolimbic activity, consistent with network-level stabilization of prefrontal–hippocampal circuits [175,199].”
From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [199]
Experimental — accuracy not yet measured
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–302 of 302
Doheny, H. C., Whittington, M. A., Jefferys, J. G. R., & Patsalos, P. N. (2002) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704606 · Cited by 35 · cited 1×
“model of focal impaired awareness epilepsy (before known as partial complex seizure) [208].”
BackgroundSuspected Levetiracetam-Induced Rhabdomyolysis: A Case Report and Literature Review
Moinuddin, I. (2020) · American Journal of Case Reports · doi:10.12659/ajcr.926064 · Cited by 35
Neuroprotective and Angiogenesis Effects of Levetiracetam Following Ischemic Stroke in Rats
Yao, X., Yang, W., Ren, Z., Zhang, H., Shi, D., Li, Y., Yu, Z., Guo, Q., Yang, G., Gu, Y., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.638209 · Cited by 35 · cited 2×
“Abbreviations 3-Nitrotyrosine (3-NT); 8-Hydroxy-2-Deoxyguanosine (8-OHdG); Activator Protein-1 (AP-1); Adenosine-Triphosphate (ATP)-Binding Cassette Sub-Family B Member 1 (ABCB1); Alpha-Amino-3Hydroxy-5-Methyl-4-Isoxazole Propionic Acid (AMPA); Angiopoietin-2 (Tie-2); Antiepileptic Drugs (AEDs); Blood-Brain Barrier (B…”
BackgroundMarini, H. R., Altavilla, D., Bellomo, M., Adamo, E. B., Marini, R., Laureanti, F., Bonaccorso, M. C., Seminara, P., Passaniti, M., Minutoli, L., et al. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.03.023 · Cited by 34 · cited 2×
“Previous administration of LEV (50 mg/kg) in rats injured with kainic acid resulted in a significant decrease in the death of hippocampal CA1 neurons and this was partially mediated by inhibition of lipoperoxidation [242].”
BackgroundAbram, M., Rapacz, A., Mogilski, S., Latacz, G., Lubelska, A., Kaminski, R. M., & Kamiński, K. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00257 · Cited by 34 · cited 13×
“In the post-synapse, LEV blocks the effect of the (12) GABAA receptor antagonists.”
BackgroundInfluentialShi, J., Anderson, D., Lynch, B. A., Castaigne, J.-G., Foerch, P., & Lebon, F. (2011) · Biochemical Society Transactions · doi:10.1042/bst0391341 · Cited by 33 · cited 5×
“Shi et al. found 14 residues that, when mutated, alter the binding of LEV to SV2A, they were: F277A, W300A, W300F, Y462A, K694A, G303A, F658A, V661A, I663A, W666A, N667A, S294A, M301A, and G659A [104].”
BackgroundInfluentialOliveira, A. A., Nogueira, C. R. A., Nascimento, V. S., Aguiar, L. M. V., Freitas, R. D. M. O. F., de Sousa, F. C. F., Viana, G. S. D. B., & Fonteles, M. M. D. F. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.05.048 · Cited by 33 · cited 1×
“) prevented the development of the SE induced by pilocarpine and decreased neuronal death in mice [205].”
BackgroundCifelli, P., Palma, E., Roseti, C., Verlengia, G., & Simonato, M. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00108 · Cited by 32 · cited 3×
“In temporal lobe epilepsy (TLE) both in animal models and patients, a run-down current elicited by GABA, which is disease progression-dependent, has been reported [152,153]; the repetitive activation of GABAA receptors induces a decrease in GABAergic signaling (current) use-dependent in hippocampal and cortical neuron…”
BackgroundWang, M., Jiang, L., & Tang, X. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s143966 · Cited by 32 · cited 1×
“reported that LEV (dosage of 60 mg/kg/day and a therapeutic course of 6 months) improved behavioral and cognitive functions in pediatric patients with autism spectrum disorder [74].”
BackgroundHaznedar, P., Doğan, Ö., Albayrak, P., Tuncer, G. Ö., Teber, S., Deda, G., & Eminoğlu, F. T. (2019) · Epilepsy Research · doi:10.1016/j.eplepsyres.2019.03.009 · Cited by 32 · cited 1×
“Several clinical studies have shown that LEV modified the antioxidant/oxidant status in patients with epilepsy [284,285], this AED increased the oxidative state (MDA, 15F2t-isoprostane and 8-OHdG markers) in patients diagnosed with epilepsy [286,287], and significantly increase the 8-OHdG levels in combination with va…”
BackgroundChronic valproate or levetiracetam treatment does not influence cytokine levels in humans
Guenther, S. P. W., Bauer, S., Hagge, M., Knake, S., Olmes, D. G., Tackenberg, B., Rosenow, F., & Hamer, H. M. (2014) · Seizure · doi:10.1016/j.seizure.2014.04.011 · Cited by 31 · cited 1×
“The prospective clinical trial of 21 epileptic patients treated with LEV (1464 ± 405 mg/day), showed a decrease in the percentage of T-lymphocytes (CD4+ CD25+) without significant changes in leukocytes, neutrophils, total lymphocytes, and cytokine levels (IL-1β, IL-6, TNF-α and monocyte chemoattractant protein-1, MCP-…”
BackgroundEffects of levetiracetam on spike and wave discharges in WAG/Rij rats
Bouwman, B. M., & van Rijn, C. M. (2004) · Seizure · doi:10.1016/j.seizure.2004.02.001 · Cited by 31 · cited 1×
“LEV was also effective in animal models of chronic epilepsy, including genetic models (Genetic Absence Epilepsy Rat from Strasbourg, GAERS) and WAG/Rij rats [209,210], as well as in a rodent model of neonatal hypoxic seizures, where LEV pretreatment (50 mg/kg) resulted in a decrease in both behavioral seizure duration…”
MethodTokudome, K., Okumura, T., Terada, R., Shimizu, S., Kunisawa, N., Mashimo, T., Serikawa, T., Sasa, M., & Ohno, Y. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00210 · Cited by 31
Costa, A., Lucchi, C., Malkoç, A., Rustichelli, C., & Biagini, G. (2021) · Pharmaceuticals · doi:10.3390/ph14020127 · Cited by 30
(2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.5 · Cited by 30
Lee, J., Daniels, V., Sands, Z. A., Lebon, F., Shi, J., & Biggin, P. C. (2015) · PLOS ONE · doi:10.1371/journal.pone.0116589 · Cited by 29 · cited 12×
“found by molecular modeling [105,106] (Figure 2).”
BackgroundMethodInfluentialSarangi, S. C., Pattnaik, S. S., Katyal, J., Kaleekal, T., & Dinda, A. K. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112389 · Cited by 29 · cited 1×
“) in a kindling model of epilepsy induced by PTZ in rats, the oxidant status in epilepsy was decreased with the use of this AED [24,275].”
BackgroundDaniels, V, Wood, M., Leclercq, K., Kaminski, R. M., & Gillard, M. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12192 · Cited by 28 · cited 5×
“multiple interacting binding sites [91].”
BackgroundInfluentialAbdel‐Wahab, B. A., Shaikh, I. A., Khateeb, M. M., & Habeeb, M. S. (2015) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2015.05.020 · Cited by 27 · cited 1×
“The same observation was shown in the kindling model of epilepsy-induced by PTZ, where the nitrite, 8-OHdG, and lipoperoxidation levels were significantly reduced, and GSH, GPx, and SOD were increased for chronic treatment with LEV [273,274].”
BackgroundAdriana, P. M. L., Alcira, R. M. B., Jatziri, C. G. I., Zamudio, S., Luis, C. P. J., Berenice, S. H. K., & Griselda, M. T. J. (2018) · Epilepsy Research · doi:10.1016/j.eplepsyres.2018.01.004 · Cited by 27 · cited 4×
“We show through a microdyalisis analysis that LEV treatment for one week (300 mg/kg/day) can induce an increase to GABA release in response to potassium-induced depolarization in the hippocampus of epileptic rats and restored the GABA/glutamate balance [150].”
BackgroundInfluentialSelf-citationFalsaperla, R., Scalia, B., Giugno, A., Pavone, P., Motta, M., Caccamo, M., & Ruggieri, M. (2021) · The Italian Journal of Pediatrics/Italian journal of pediatrics · doi:10.1186/s13052-021-01027-2 · Cited by 27 · cited 1×
“A good clinical response to LEV was also seen in early-onset genetic epilepsy in both term and preterm infants [37,38].”
BackgroundContreras‐García, I. J., Gómez‐Lira, G., Phillips-Farfán, B. V., Pichardo‐Macías, L. A., García‐Cruz, M. E., Chávez-Pacheco, J. L., & Mendoza‐Torreblanca, J. G. (2021) · Brain Sciences · doi:10.3390/brainsci11050531 · Cited by 27 · cited 1×
“Recently we found that the SV2A expression in glutamatergic terminals was a key element for the response to LEV [133].”
BackgroundSelf-citationFosL1 Is a Novel Target of Levetiracetam for Suppressing the Microglial Inflammatory Reaction
Niidome, K., Taniguchi, R., Yamazaki, T., Tsuji, M., Itoh, K., & Ishihara, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010962 · Cited by 26 · cited 1×
“Therefore, the authors suggested that LEV can be a candidate for the treatment of neurological diseases that involve microglial activation [184].”
BackgroundSeletracetam, a small molecule SV2A modulator for the treatment of epilepsy.
Pollard, J. R. (2008) · PubMed · Cited by 25
Efficacy and Safety of Levetiracetam for Outpatient Alcohol Detoxification
Müller, C. R., Schäfer, M., Schneider, S., Heimann, H., Hinzpeter, A., Volkmar, K., Förg, A., Heinz, A., & Hein, J. (2010) · Pharmacopsychiatry · doi:10.1055/s-0030-1249098 · Cited by 25 · cited 1×
“safety of LEV (dosage regime between 500 and 4000 mg/day for a maximum of 7 days) for outpatient alcohol detoxification; alcohol withdrawal syndrome decreased over 5 days after treatment that included LEV [80].”
BackgroundLeniger, T., Thöne, J., Bonnet, U., Hufnagel, A., Bingmann, D., & Wiemann, M. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705836 · Cited by 25 · cited 2×
“Then, since acidifications induced by LEV were based upon an inhibition of the Na/HCO3 co-transporters, Na+-dependent HCO3 transporters and Na+-dependent Cl/HCO3 exchangers, LEV may decrease the intracellular pH by weakening the transmembrane HCO3-mediated acid extrusion [20,174].”
BackgroundLevetiracetam attenuates rotenone-induced toxicity: A rat model of Parkinson's disease
Erbaş, O., Yılmaz, M., & Taşkıran, D. (2016) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2016.02.005 · Cited by 25 · cited 1×
“for 21 days) significantly decreased the lipoperoxidation levels and increases GSH, CAT, and SOD levels in the brain [279].”
BackgroundCalame, D. G., Herman, I., & Riviello, J. J. (2021) · Epilepsy & Behavior Reports · doi:10.1016/j.ebr.2020.100425 · Cited by 25 · cited 1×
“Gly660Arg), seizures were found to worsen after treatment with increasing doses of LEV for approximately 40 days [192].”
BackgroundBesli, G. E., Karatoprak, E., & Yılmaz, S. (2020) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2020.107289 · Cited by 24 · cited 15×
“Moreover, Wolking et al. investigated the genetic risk of rare variants for drug response to three AEDs (including LEV treatment for at least 1 year) through an analysis of the sequencing, genotyping, variant selection, and annotation of an epileptic cohort derived from the EpiPGX Consortium, to identify genetic bioma…”
BackgroundInfluentialThe effect of levetiracetam on status epilepticus-induced neuronal death in the rat hippocampus
Lee, D.-S., Ryu, H. J., Kim, J.-E., Choi, H., Kim, Y.-I., Song, H., & Kang, T. (2013) · Seizure · doi:10.1016/j.seizure.2013.02.005 · Cited by 23 · cited 1×
“In contrast, when LEV was administered as an adjunct to diazepam, the neuroprotective effect was not observed compared to when it was administered alone [243].”
ResultLevetiracetam in the treatment of vascular chorea: a case report
D’Amelio, M., Callari, G., Gammino, M., Saia, V., Lupo, I., Salemi, G., Ragonese, P., & Savettieri, G. (2004) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-004-0842-0 · Cited by 23 · cited 1×
“reported a marked improvement on movement disorders in a 74-year-old woman with hemichorea after LEV treatment (the treatment started with 250 mg/day, seven days later the dosage was increased up to 250 mg twice a day till remission of choreic movements) [71].”
BackgroundTreatment of Juvenile Myoclonic Epilepsy
Auvin, S. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00046.x · Cited by 22 · cited 1×
“LEV has also shown good efficacy in patients with reflex seizures (for a review see [30]) and is probably the best new AED for the treatment of juvenile myoclonic epilepsy because of a high and sustained efficacy [31].”
BackgroundAntiepileptogenic effects of Ethosuximide and Levetiracetam in WAG/Rij rats are only temporary
Leo, A., Caro, C. D., Nesci, V., Palma, E., Tallarico, M., Iannone, M., Constanti, A., Sarro, G. D., Russo, E., & Citraro, R. (2019) · Pharmacological Reports · doi:10.1016/j.pharep.2019.04.017 · Cited by 22 · cited 1×
“[223] WAG/Rij rats Rat model of absence epilepsy 80 mg/kg/day i.”
BackgroundMorimoto, M., Hashimoto, T., Kitaoka, T., & Kyotani, S. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3289w · Cited by 21
Hansson, E., Björklund, U., Skiöldebrand, E., & Rönnbäck, L. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1361-8 · Cited by 21 · cited 2×
“Recent evidence in different animal models, suggests that LEV exerts neuroprotective effects via anti-inflammatory and antioxidant effects [178,244,270].”
BackgroundDetermination of levels of oxidative stress and nitrosative stress in patients with epilepsy
Erşan, S., Çiğdem, B., Bakır, D., & Doğan, H. O. (2020) · Epilepsy Research · doi:10.1016/j.eplepsyres.2020.106352 · Cited by 21 · cited 1×
“Several clinical studies have shown that LEV modified the antioxidant/oxidant status in patients with epilepsy [284,285], this AED increased the oxidative state (MDA, 15F2t-isoprostane and 8-OHdG markers) in patients diagnosed with epilepsy [286,287], and significantly increase the 8-OHdG levels in combination with va…”
BackgroundZhao, T., Yu, J., Wang, T., Feng, J., Zhao, W., Sun, L., Yu, L., Li, H., & Sun, Y. (2020) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000805 · Cited by 21 · cited 2×
“The authors concluded that ABCB1 rs2032582 and rs1045642 polymorphisms may affect the therapeutic efficacy of LEV in epilepsy [191].”
BackgroundHow about Levetiracetam in Glioblastoma? An Institutional Experience and Meta-Analysis
Jabbarli, R., Ahmadipour, Y., Rauschenbach, L., Santos, A. N., Oppong, M. D., Pierscianek, D., Quesada, C. M., Kebir, S., Dammann, P. R., Guberina, N., et al. (2021) · Cancers · doi:10.3390/cancers13153770 · Cited by 21
Chen, W., Tan, Y., Ge, Y.-X., Chen, Y., & Liu, X. (2015) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-015-0683-8 · Cited by 20
Levetiracetam resistance: Synaptic signatures & corresponding promoter SNPs in epileptic hippocampi
Grimminger, T., Pernhorst, K., Surges, R., Niehusmann, P., Priebe, L., von Lehe, M., Hoffmann, P., Cichon, S., Schoch, S., & Becker, A. J. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.08.015 · Cited by 20 · cited 2×
“The authors suggest that epigenetic factors predisposing for a priori LEV pharmacoresistance by transcriptional targets [194].”
BackgroundHigh-field MRS study of GABA+ in patients with migraine
Li, Q., Chen, C.-F., & Gong, T. (2018) · Neuroreport · doi:10.1097/wnr.0000000000001067 · Cited by 20 · cited 1×
“Meanwhile, migraine patients treated with LEV showed a decrease in headache frequency and intensity associated with a decrease in posterior cingulate cortex GABA levels [147].”
BackgroundChen, D., Bian, H., & Zhang, L. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s188111 · Cited by 20 · cited 2×
“LEV treatment can promote infections such as pharyngitis, nasopharyngitis, and rhinitis [48,54,55].”
BackgroundPang, X., Liang, X., Zhou, X., Liu, J.-P., Zhang, Z., & Zheng, J. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04322-8 · Cited by 20 · cited 1×
“Moreover, a recent study indicated that epileptic patients treated with LEV showed increased functional connectivity compared to healthy subjects [238], relating to normalization of left medial temporal lobe deactivation during verbal performance [239].”
BackgroundLima, R., Gomes, E. D., Cibrão, J. R., Rocha, L. A., Assunção-Silva, R. C., Rodrigues, C. S., Neves‐Carvalho, A., Monteiro, S., Salgado, A. J., & Silva, N. A. (2021) · npj Regenerative Medicine · doi:10.1038/s41536-021-00121-7 · Cited by 20 · cited 2×
“In contrast, in serum samples from rats with spinal cord injury, LEV did not decrease levels of IL-1β, IL-6, IL-10, interferon γ (IFNγ), TNFα, and IL-4 in 1- and 24-h post injury [254].”
BackgroundEffect of valproate and add-on levetiracetam on inflammatory biomarkers in children with epilepsy
Labh, R., Gupta, R., Narang, M., Halder, S., & Kar, R. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.108358 · Cited by 20 · cited 1×
“Additionally, both drugs reduced anxiety and improved quality of life in these pediatric patients [296].”
BackgroundAnimal Models Used in the Screening of Antiepileptic Drugs
Kupferberg, H. J. (2001) · Epilepsia · doi:10.1046/j.1528-1157.2001.00002.x · Cited by 20
A New Alternative Drug With Fewer Adverse Effects in the Treatment of Sydenham Chorea
Şahin, S., & Cansu, A. (2015) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000084 · Cited by 19 · cited 1×
“Other reports have found that LEV (250 mg/day) is an option for the treatment of Sydenham chorea movement disorders in children because of the tolerability and safety profile [72,73].”
BackgroundEfficacy and safety of levetiracetam in the off-label treatment of neonatal seizures
Liu, B., Jiang, L., Li, X., Hong, S., Chen, W., & Hu, Y. (2019) · International Journal of Neuroscience · doi:10.1080/00207454.2019.1687469 · Cited by 19 · cited 1×
“Gastrointestinal reactions such as vomiting, nausea and anorexia have also been reported [50,59,60].”
BackgroundSolaro, C. M., Alessandro de, S. I. R. E., Uccelli, M. M., Mueller, M., Bergamaschi, R., Gasperini, C., Restivo, D. A., Stabile, M. R., & Patti, F. (2020) · European Journal of Neurology · doi:10.1111/ene.14403 · Cited by 19 · cited 1×
“They found that LEV (daily drug regimen started with a dose of LEV 500 mg) was effective on upper limb movement in MS patients with cerebellar signs [69].”
BackgroundContreras-García, I. J., Pichardo-Macías, L. A., Santana-Gómez, C. E., Sánchez-Huerta, K., Ramírez-Hernández, R., Gómez-González, B., Rocha, L., & Mendoza Torreblanca, J. G. (2018) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2018.08.023 · Cited by 18 · cited 1×
“sion associated with GABAergic but no with glutamatergic terminals was reported [165].”
BackgroundSelf-citationAnalysis of Differential Expression of Synaptic Vesicle Protein 2A in the Adult Rat Brain
Mendoza-Torreblanca, J. G., García-Cruz, M. E., Sánchez-Cruz, I., Gomez-Gonzalez, B., Juárez-Méndez, S., & Gómez-Lira, G. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.09.004 · Cited by 18 · cited 1×
“These data agree with the observations of a great co-expression between SV2A and GABAergic neurons in the amygdala and hippocampus [163,164,166,167].”
ResultSelf-citationSantana‐Gomez, C., Valle-Dorado, M. G., Domínguez-Valentín, A. E., Hernández-Moreno, A., Orozco-Suárez, S. A., & Rocha, L. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.09.004 · Cited by 18 · cited 1×
“Moreover, some reports have shown that LEV did not prevent acquired epilepsy when administered in post-SE animal models of TLE, although it did exert neuroprotective effects [225,246,247].”
BackgroundAlrabiah, H. K. (2019) · Profiles of drug substances, excipients, and related methodology · doi:10.1016/bs.podrm.2019.02.003 · Cited by 18
Feng, Y., Chen, Y., Jia, Y., Wang, Z., Wang, X., Jiang, L., Ai, C., Li, W., & Liu, Y. (2021) · Seizure · doi:10.1016/j.seizure.2021.07.012 · Cited by 17 · cited 1×
“Based on this kind of evidence, LEV has been considered as a first option for second-line therapy in the treatment of SE (for a review see [46]).”
BackgroundAnti-inflammatory effects of levetiracetam in experimental autoimmune encephalomyelitis
Thöne, J., Ellrichmann, G., Faustmann, P. M., Gold, R., & Haghikia, A. (2012) · International Immunopharmacology · doi:10.1016/j.intimp.2012.05.021 · Cited by 16 · cited 1×
“Moreover, in a mouse model of multiple sclerosis has been showed that LEV modulates the gene expression of IL-1β and tumoral growth factor-1beta (TGF-1β) acting as an anti-inflammatory [294].”
BackgroundXiong, J., Zhou, H., Lu, D., Wang, Z., Liu, H.-J., Sun, Y., Xu, J., Feng, Y., & Xing, A. (2020) · Medical Science Monitor · doi:10.12659/msm.922741 · Cited by 16 · cited 4×
“Using the BV-2 cell line and liposaccharide stimulation (inflammatory model of microglia in vitro), it was demonstrated that 50 μg/mL of LEV decreased the mRNA levels of IL-1β and TNF-α, and significantly decreased protein expression of NF-kB-light-chain-enhancer of activated B cells and signal transducer and activato…”
BackgroundMethodInfluentialFunctional characterization of the antiepileptic drug candidate, padsevonil, on GABA A receptors
Niespodziany, I., Ghisdal, P., Mullier, B., Wood, M. D., Provins, L., Kaminski, R. M., & Wolff, C. (2020) · Epilepsia · doi:10.1111/epi.16497 · Cited by 16 · cited 13×
“In the post-synapse, LEV blocks the effect of the (12) GABAA receptor antagonists.”
BackgroundInfluentialEfficacy of levetiracetam in the treatment of Sydenham chorea
Direk, M. Ç., Epçaçan, S., Epçaçan, Z. K., Yıldırım, D. D., & Okuyaz, Ç. (2020) · Pediatrics International · doi:10.1111/ped.14318 · Cited by 16 · cited 1×
“Other reports have found that LEV (250 mg/day) is an option for the treatment of Sydenham chorea movement disorders in children because of the tolerability and safety profile [72,73].”
BackgroundHassel, B., Taubøll, E., Shaw, R. N., Gjerstad, L., & Dingledine, R. J. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2010.02545.x · Cited by 15 · cited 1×
“Therefore, LEV can affect gene expression [122,185,186].”
Gulcebi, M. I., Kendırlı, M. T., Aşık, Z. N. T., Patsalos, P. N., & Onat, F. (2018) · Epilepsy Research · doi:10.1016/j.eplepsyres.2018.09.015 · Cited by 15 · cited 1×
“found a decrease in the IL1β concentration in patients on monotherapy with LEV for at least one month [297].”
BackgroundYang, L., Dong, X., Cui, X., Liu, J., Liu, W.-N., & Zhang, L. (2021) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2021.05.004 · Cited by 15 · cited 1×
“Interestingly, in meta-analysis studies, LEV was found to be significantly effective for seizure cessation in patients with SE [44,45].”
BackgroundOsuntokun, O. S., Abdulwahab, U. F., Akanji, N. O., Adedokun, K. I., Adekomi, A. D., & Olayiwola, G. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136167 · Cited by 15
Kawai, M., Goji, H., & Kanemoto, K. (2021) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2021.108493 · Cited by 15
Kulick, C. V., Gutherz, S. B., Beck, V. C., Medvedeva, N., Soper, C., & Forcelli, P. A. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.09.016 · Cited by 14 · cited 1×
“In addition, in postnatal day 10 rat pups, treatment with LEV decreased the severity of DMCM-evoked seizures in a dose-dependent manner when administered in doses of 10 mg/kg and greater [157].”
MethodLevetiracetam-induced eosinophilic pneumonia
Fagan, A. B., Fuld, J. P., & Soon, E. (2017) · BMJ Case Reports · doi:10.1136/bcr-2016-219121 · Cited by 14 · cited 1×
“Additionally, hematologic adverse effects (thrombocytopenia, eosinophilia, and rarely pancytopenia) have been reported with the use of LEV [61,62].”
BackgroundChu, S.-S., Wang, H., Zhu, L.-N., Xu, D., Wang, X., & Liu, L. (2019) · Seizure · doi:10.1016/j.seizure.2019.11.007 · Cited by 14 · cited 1×
“Interestingly, in meta-analysis studies, LEV was found to be significantly effective for seizure cessation in patients with SE [44,45].”
BackgroundMalatyńska, E., Knapp, R., Ikeda, M., & Yamamura, H. I. (1989) · Brain Research Bulletin · doi:10.1016/0361-9230(89)90028-2 · Cited by 13
Solaro, C. M., Brichetto, G., Capello, E., Abuarqub, S., & Sanguineti, V. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2008.02129.x · Cited by 13 · cited 1×
“had similar results with a daily dose of 1500 mg LEV [70].”
ResultThe effects of levetiracetam on urinary 15f-2t-isoprostane levels in epileptic patients
Özden, H., Kabay, S. C., Toker, A., Üstüner, M. C., Özbayer, C., Üstüner, D., & Güneş, H. V. (2010) · Seizure · doi:10.1016/j.seizure.2010.07.010 · Cited by 13 · cited 1×
“Several clinical studies have shown that LEV modified the antioxidant/oxidant status in patients with epilepsy [284,285], this AED increased the oxidative state (MDA, 15F2t-isoprostane and 8-OHdG markers) in patients diagnosed with epilepsy [286,287], and significantly increase the 8-OHdG levels in combination with va…”
BackgroundParveen, B., Tripathi, M., & Vohora, D. (2018) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12996 · Cited by 13 · cited 1×
“This study showed that the LEV effect is implicated the modulation of the Wnt signaling pathway [182].”
BackgroundLevetiracetam treatment ameliorates LRRK2 pathological mutant phenotype
Rassu, M., Biosa, A., Galioto, M., Fais, M., Sini, P., Greggio, E., Piccoli, G., Crosio, C., & Iaccarino, C. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14674 · Cited by 13 · cited 2×
“These results indicated that LEV reverts LRRK2 G2019S-associated pathological effects and that LRRK2 and SV2A are involved in a common protein network controlled by LEV with the consequent modulation of traffic and dynamics in neurons [179].”
BackgroundA Comparison of Seizure Prophylaxis: Phenytoin Versus Levetiracetam
Fiani, B., Andraos, C., Mabry, I., & Siddiqi, J. (2021) · Cureus · doi:10.7759/cureus.14956 · Cited by 13
Pichardo‐Macías, L. A., Contreras‐García, I. J., Zamudio, S., Mixcoha, E., & Mendoza‐Torreblanca, J. G. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-6355-3_4 · Cited by 12 · cited 3×
“activity, pathophysiology of the nervous tissue and by SV2A expression [111].”
BackgroundSelf-citationLevetiracetam in Men with Epilepsy: Testosterone is Left Alone but Sperm Count is Paramount
Spencer, D. C. (2017) · Epiliepsy currents/Epilepsy currents · doi:10.5698/1535-7511.17.2.99 · Cited by 12
Wong, L. C., Freeburg, J. D., Montouris, G., & Hohler, A. D. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.11.007 · Cited by 11 · cited 1×
“Several studies have shown the promising potential of the anti-hyperalgesic and anti-inflammatory alternative [12].”
BackgroundHigh-Dose Levetiracetam for Neonatal Seizures: A Retrospective Review
Hnaini, M., Darwich, M., Koleilat, N., Jaafar, F., Hanneyan, S., Rahal, S. S., Mikati, I. E., Shbarou, R. M., Nabout, R. A. E., Maalouf, F. I., et al. (2020) · Seizure · doi:10.1016/j.seizure.2020.08.030 · Cited by 11 · cited 1×
“Although LEV has no known serious adverse effects on organ systems, even at highdose regimens [52], and has fewer drug-related adverse reactions than other common AEDs [53], some adverse effects have been reported (for a review see [54]).”
BackgroundDircio-Bautista, M., Colín-González, A. L., Aguilera, G., Maya-López, M., Villeda‐Hernández, J., Galván‐Arzate, S., García, E., Túnez, I., & Santamaría, A. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9836-4 · Cited by 10 · cited 1×
“administered for 7 days) through its antioxidant action has also been observed in the striatum of rats that were administered a neurotoxin that induces excitotoxicity [278].”
BackgroundLevetiracetam Affects Differentially Presynaptic Proteins in Rat Cerebral Cortex
Marcotulli, D., Fattorini, G., Bragina, L., Perugini, J., & Conti, F. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00389 · Cited by 10 · cited 1×
“In contrast, in the neocortex of non-epileptic rats, no significant differences were detected in SV2A protein levels in LEV-treated animals compared to controls [134].”
ResultImran, I., Koch, K. A., Schöfer, H., Lau, H., & Klein, J. (2019) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps30439 · Cited by 10
Hughes, K., Garrity, L. C., Nelson, A. S., Lane, A., & Teusink‐Cross, A. (2021) · Pediatric Transplantation · doi:10.1111/petr.14026 · Cited by 10
Levetiracetam ameliorates ovarian function in streptozotocin-induced diabetic rats
Akman, L., Erbaş, O., Akdemir, A., Yavaşoğlu, A., Taşkıran, D., & Kazandı, M. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1032931 · Cited by 9 · cited 1×
“) reduces lipoperoxidation, and increases total antioxidant capacity [280,281].”
BackgroundSugaya, Y., Jinde, S., Kato, N., & Maru, E. (2009) · Neuroscience Research · doi:10.1016/j.neures.2009.10.014 · Cited by 9 · cited 1×
“[222] Rat perforant path kindling model 100 mg/kg, i.”
BackgroundDeriaz, N., Willi, J., Orihuela-Flores, M., Carminati, G. G., & Ratib, O. M. (2011) · Neurocase · doi:10.1080/13554794.2011.627336 · Cited by 9 · cited 1×
“reported that LEV in a dose of 2 g/day over two weeks controlled de self-injurious behavior (including bruising of the limbs and biting of the tongue and lips) in a patient with pervasive developmental disorders, severe intellectual disability, and seizures, and the symptoms disappeared with no recurrence 2 years late…”
BackgroundMorimoto, M., Satomura, S., Hashimoto, T., & Kyotani, S. (2016) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2016.10.005 · Cited by 9
Mahdavi, A., Naeini, A. A., Najafi, M. R., Maracy, M. R., & Ghazvini, M. (2020) · African Health Sciences · doi:10.4314/ahs.v20i2.55 · Cited by 9 · cited 1×
“Several clinical studies have shown that LEV modified the antioxidant/oxidant status in patients with epilepsy [284,285], this AED increased the oxidative state (MDA, 15F2t-isoprostane and 8-OHdG markers) in patients diagnosed with epilepsy [286,287], and significantly increase the 8-OHdG levels in combination with va…”
BackgroundEsang, M., Santos, M. G., & Ahmed, S. (2020) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.19nr02502 · Cited by 9 · cited 1×
“The LEV doses and/or duration reported in the analyzed studies were 500 mg, 1000 mg, and 3000 mg for epilepsy (n = 517), 500 mg/twice/day (previously 250 mg twice/day) for depression (n = 23), 2000 mg twice/day (previously 1000 mg/day) for alcohol dependence (n = 66), 1500 mg twice/day for bipolar disorder (n = 41), 5…”
BackgroundFrycia, A., Starck, J., Jadot, S., Lallemand, B., Leclercq, K., Brutto, P. L., Matagne, A., Verbois, V., Mercier, J., & Kenda, B. (2009) · ChemMedChem · doi:10.1002/cmdc.200900436 · Cited by 8 · cited 1×
“The structural change in this molecule highlighted the importance of position 4, the size of the chain, and the chirality of the group present in position 1 of 2-oxopyrrolidine [90] (Figure 1C).”
BackgroundBonnet, U., Bingmann, D., Speckmann, E., & Wiemann, M. (2018) · Brain Research · doi:10.1016/j.brainres.2018.12.039 · Cited by 8 · cited 3×
“Then, by inducing intracellular acidification, LEV may attenuate the excitatory neuronal activity, promoting the termination of epileptic activity and contributing to its anticonvulsive potency [20].”
BackgroundBehavioral alterations associated with levetiracetam in pediatric epilepsy
Cortés, C., & Manterola, C. (2020) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2020.107472 · Cited by 8
Abdelmesih, S. K., Elkhateeb, N. M., Zakaria, M., & Girgis, M. Y. F. (2021) · Seizure · doi:10.1016/j.seizure.2021.06.033 · Cited by 8 · cited 1×
“Generalized-onset tonic-clonic seizures are a common type of seizure in childhood epilepsy, and treatment with LEV has shown favorable results in pediatric patients with this class of seizures [36].”
BackgroundHamza, M., Anderson, D. G., Snyder, J. W., Deschner, S., & Cifu, D. X. (2009) · PM&R · doi:10.1016/j.pmrj.2008.12.004 · Cited by 7 · cited 1×
“reported the effectiveness of LEV (initially received LEV 500 mg twice a day for 2 weeks, increasing to 750 mg twice day for 2 weeks, and then to 1500 mg twice a day) in the reduction in pain in chronic lumbar radiculopathy [67].”
BackgroundCharles Bonnet syndrome successfully treated with levetiracetam
Grüter, T., Ayzenberg, I., Gold, R., & Börnke, C. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8240-y · Cited by 7 · cited 1×
“Plus, the use of LEV has been proposed for eclampsia management in pregnancy (administered as 1 g loading dose followed by 500 mg intravenously bd in 10 cases) and in Charles Bonnet syndrome (administered 500 mg twice a day for 1 day and after a dosage up to 750 mg twice for 1 day and the hallucinations completely dis…”
MethodRelationship of levetiracetam and obsessive-compulsive disorder: a case report
Çökmüş, F. P., Aşçıbaşı, K., Öztekin, S., & Demet, M. M. (2017) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2017.1342798 · Cited by 6 · cited 1×
“In obsessive-compulsive disorder, LEV is recommended in a dose of 1500 mg/day [78].”
BackgroundLevetiracetam improves symptoms of multiple chemical sensitivity: Case report
Kakisaka, Y., Jin, K., Fujikawa, M., Kitazawa, Y., Kato, K., & Nakasato, N. (2017) · The Journal of Medical Investigation · doi:10.2152/jmi.64.296 · Cited by 6 · cited 1×
“also reported a clinical case where LEV (250 mg/day for two days) improved multiple chemical sensitivity disorder [83].”
BackgroundSatia, M., & Shilotri, M. (2016) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20164325 · Cited by 5 · cited 1×
“Plus, the use of LEV has been proposed for eclampsia management in pregnancy (administered as 1 g loading dose followed by 500 mg intravenously bd in 10 cases) and in Charles Bonnet syndrome (administered 500 mg twice a day for 1 day and after a dosage up to 750 mg twice for 1 day and the hallucinations completely dis…”
MethodEfficacy of levetiracetam in premature infants: our experience and review of the literature
Özalkaya, E., Topçuoğlu, S., Karatepe, H. Ö., Tüten, A., Gökmen, T., & Karatekın, G. (2018) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2018.1481946 · Cited by 5 · cited 1×
“A good clinical response to LEV was also seen in early-onset genetic epilepsy in both term and preterm infants [37,38].”
BackgroundThe Efficacy and Safety Profile of Generic Intravenous Levetiracetam in a Real-World Setting
Ruangritkul, P., Tiamkao, S., Chainirun, N., Pranboon, S., Tiamkao, S., Sawanyawisuth, K., & Khamsai, S. (2021) · Current Therapeutic Research · doi:10.1016/j.curtheres.2021.100648 · Cited by 5 · cited 2×
“Gastrointestinal reactions such as vomiting, nausea and anorexia have also been reported [50,59,60].”
BackgroundBayhan, I., Turtay, M., Çiftçi, O., Çetin, A., Başak, N., Öztanır, M. N., Oğuztürk, H., Gürbüz, Ş., & Güven, T. (2020) · PubMed · doi:10.26355/eurrev_202006_21702 · Cited by 4 · cited 1×
“Moreover, SOD and GSH levels were also significantly increased [272].”
BackgroundLevetiracetam-Induced Hepatic Dysfunction
Gayatri, P., Selvam, M., & Sreeharsha, S. (2020) · Neurology India · doi:10.4103/0028-3886.293452 · Cited by 4
Prophylactic levetiracetam-induced pancytopenia with traumatic extra-dural hematoma: Case report
Bangash, O. K., Simonin, A., Tsimiklis, C., Ramakonar, H., & Honeybul, S. (2020) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2020.08.004 · Cited by 4 · cited 1×
“Additionally, hematologic adverse effects (thrombocytopenia, eosinophilia, and rarely pancytopenia) have been reported with the use of LEV [61,62].”
BackgroundFayyazi, A., Ebrahimi, M. H., Roshanaei, G., & Bazmamoun, H. (2021) · Iranian journal of child neurology. · doi:10.22037/ijcn.v16i1.30946 · Cited by 3 · cited 1×
“However, the addition of LEV normalized EEG faster [42].”
BackgroundMoon, J. U., & Han, J. Y. (2021) · Brain Sciences · doi:10.3390/brainsci11111452 · Cited by 2 · cited 1×
“Gastrointestinal reactions such as vomiting, nausea and anorexia have also been reported [50,59,60].”
Background
Research works printed but not linked: 1
- Christine, A.G., and Devaskar, S.U. (2012). Chapter 61—Central Nervous System Injury and Neuroprotection. Avery’s Diseases of the Newborn (Ninth Edition), W.B. Saunders.
Cited by
Mitochondrial dysfunction and neurological disorders: A narrative review and treatment overview
Alshial, E. E., Abdulghaney, M. I., Wadan, A. S., Abdellatif, M. A., Ramadan, N. E., Suleiman, A. M., Waheed, N., Abdellatif, M., & Mohammed, H. S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122257 · Cited by 98
Neuroinflammation and status epilepticus: a narrative review unraveling a complex interplay
Foiadelli, T., Santangelo, A., Costagliola, G., Costa, E., Scacciati, M., Riva, A., Volpedo, G., Smaldone, M. C., Bonuccelli, A., Clemente, A. M., et al. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1251914 · Cited by 91
de Castro, A. C., Nascimento, F. A., Beltrán‐Corbellini, Á., Toledano, R., García‐Morales, I., Gil‐Nagel, A., & Aledo‐Serrano, Á. (2023) · Seizure · doi:10.1016/j.seizure.2023.03.017 · Cited by 49
The AI Future of Emergency Medicine
Petrella, R. J. (2024) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2024.01.031 · Cited by 43
Current Issues in Pharmacy and Medical Sciences
(2024) · Current Issues in Pharmacy and Medical Sciences · doi:10.12923/j.2084-980x · Cited by 39
Metadata
- Authors
- Contreras-García, I. J., Cárdenas-Rodríguez, N., Romo-Mancillas, A., Bandala, C., Zamudio, S. R., Gómez-Manzo, S., Hernández-Ochoa, B., Mendoza-Torreblanca, J. G., & Pichardo-Macías, L. A.
- Affiliations
- Laboratorio de Fisiología, Escuela Militar de Graduados de Sanidad, Ciudad de México 11200, Mexico
- Laboratorio de Neurociencias, Subdirección de Medicina Experimental, Instituto Nacional de Pediatría, Ciudad de México 04530, Mexico
- Laboratorio de Diseño Asistido por Computadora y Síntesis de Fármacos, Facultad de Química, Universidad Autónoma de Querétaro, Centro Universitario, Querétaro 76010, Mexico
- Secretaria de Salud (MX)
- Instituto Politécnico Nacional (MX)
- Laboratorio de Bioquímica Genética, Instituto Nacional de Pediatría, Secretaría de Salud, Ciudad de México 04530, Mexico
- Laboratorio de Inmunoquímica, Hospital Infantil de México Federico Gómez, Secretaría de Salud, Ciudad de México 06720, Mexico
- Departamento de Fisiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 07738, Mexico
- ORCID
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2022-04-13
- Volume
- 15
- Issue
- 4
- Pages
- 475
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC9030752
- OpenAlex
- W4223993843
- Cited by
- 131
- References
- 303
- Citations by year
- 2026: 28 · 2025: 45 · 2024: 37 · 2023: 21
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
- Keywords
- levetiracetam, antiepileptic drugs, epilepsy, seizure control, SV2A, calcium homeostasis, GABAergic system, AMPA receptors, multi-target drugs, drug repurposing, neuroprotection, anti-inflammatory activity, antioxidant activity, molecular targets
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.